EFFECT OF THE DIETARY SUPPLEMENT ELEVATP ON BLOOD ATP LEVEL: AN ACUTE PILOT CLINICAL STUDY
T. Reyes-Izquierdo, B. Nemzer, R. Argumedo, C. Shu, L. Huynh, Z. Pietrzkowski
J Aging Res Clin Practice 2013;2(2):178-184
Objectives: Adenosine triphosphate (ATP) participates in a number of biological processes and its levels diminish during aging. We studied the effects of a proprietary combination of a plant-mineral-rich ancient peat material and a polyphenol-rich apple extract, marketed under the trade name elevATP™, on blood ATP levels. Design: Acute, placebo-controlled, prospective clinical trial. Participants: 18 generally healthy, adult human subjects. Intervention: A single, 150 mg dose of elevATP™ or 50 mg of encapsulated silica oxide (placebo). Measurements: Blood was collected prior to, and at 60, 90 and 120 minutes after treatment. We measured whole blood ATP, total mammalian target for rapamycin (mTOR), lactate, reactive oxygen species (ROS), and glucose. We also identified and quantified the mineral and bioactive components of elevATP™. Results: When compared to the placebo group, elevATP™ caused an acute increase in blood levels of ATP by 64% (P=0.02). ROS and lactate levels were unchanged by elevATP. Total mTOR levels in blood were modestly, but significantly, lower after treatment. Conclusion: Results show that treatment with a single dose of elevATP™ increased blood ATP levels without increasing ROS. Confirmation of these results in a larger study sample is needed. Trials in older individuals may be particularly informative.